These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 14555296

  • 1. Evaluation of a didanosin-containing regimen including genotypic resistance testing: an open-label, multicenter study.
    Treichel S, Hartmann M, Rump A, Brust J, Schuster D, Mosthaf F, Procaccianti M, Klinker H, Petzoldt D.
    Eur J Med Res; 2003 Sep 29; 8(9):405-13. PubMed ID: 14555296
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Sep 29; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 3. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov 29; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinically relevant genotype interpretation of resistance to didanosine.
    Marcelin AG, Flandre P, Pavie J, Schmidely N, Wirden M, Lada O, Chiche D, Molina JM, Calvez V, AI454-176 Jaguar Study Team.
    Antimicrob Agents Chemother; 2005 May 29; 49(5):1739-44. PubMed ID: 15855490
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct 29; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 29; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 11. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.
    Clin Ther; 2006 May 29; 28(5):745-54. PubMed ID: 16861096
    [Abstract] [Full Text] [Related]

  • 12. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
    Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, Bonmarchand M, Cacace R, David DJ, Simon A, Lamotte C, Marcelin AG, Calvez V, Bricaire F, Costagliola D, Katlama C.
    HIV Med; 2004 Sep 29; 5(5):352-9. PubMed ID: 15369510
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 29; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Mitrenga D, Beerenwinkel N, Sagir A, Pfister H, Häussinger D.
    Dtsch Med Wochenschr; 2007 May 04; 132(18):977-82. PubMed ID: 17457780
    [Abstract] [Full Text] [Related]

  • 16. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 04; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 17. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM, Marcelin AG, Pavie J, Heripret L, De Boever CM, Troccaz M, Leleu G, Calvez V, AI454-176 JAGUAR Study Team.
    J Infect Dis; 2005 Mar 15; 191(6):840-7. PubMed ID: 15717257
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Mar 15; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    Clevenbergh P, Boulmé R, Kirstetter M, Dellamonica P.
    HIV Med; 2004 Jul 15; 5(4):284-8. PubMed ID: 15236618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.